Mood Swings: Drugs That Cause or Treat Them, Plus When to Act

What Actually Causes Mood Swings?

Mood swings are rapid, often unprovoked shifts in emotional state. They range from irritability and anxiety to sadness or euphoria, sometimes cycling within hours. The underlying mechanism almost always involves a disruption in the neurotransmitter systems (serotonin, dopamine, norepinephrine) or in the hypothalamic-pituitary-gonadal axis that governs sex hormone production.

Hormonal Drivers

Estrogen and progesterone directly modulate serotonin receptor density. A 2022 analysis published in Menopause found that perimenopausal women with vasomotor symptoms were 3 times more likely to report significant mood instability than age-matched premenopausal controls (1). Progesterone metabolites also act on GABA-A receptors, so any phase of the menstrual cycle that shifts the estrogen-to-progesterone ratio can produce irritability, tearfulness, or brief depressive episodes.

Testosterone deficiency in men follows the same logic. Low free testosterone is independently associated with depressive symptoms and irritability in multiple observational cohorts (2).

Thyroid and Metabolic Causes

Both hyperthyroidism and hypothyroidism alter mood. Hyperthyroidism produces anxiety and emotional lability; hypothyroidism typically causes flat affect and depressive-spectrum symptoms. The American Thyroid Association recommends TSH screening as part of any new-onset mood evaluation (3). Blood glucose dysregulation, including reactive hypoglycemia and poorly controlled type 2 diabetes, also produces rapid mood shifts tied to glucose nadir.

Psychiatric and Sleep-Related Causes

Bipolar I and II disorder, borderline personality disorder, ADHD, and premenstrual dysphoric disorder (PMDD) all present with mood lability as a core feature. Chronic sleep deprivation of even 3 to 4 hours per night can produce mood instability indistinguishable from a psychiatric disorder on brief clinical screening (4).

Drugs That Cause Mood Swings

Several commonly prescribed medication classes are directly linked to mood instability. Recognizing the drug as the cause before adding a second prescription is a basic principle of medication reconciliation (5).

Corticosteroids

Prednisone, dexamethasone, and methylprednisolone are the most reliably documented mood-altering drugs in clinical medicine. A systematic review in the BMJ covering 14 randomized trials found mood disturbances, ranging from euphoria to severe depression and psychosis, in up to 60% of patients on doses above 40 mg prednisone-equivalent per day (6). The mechanism involves direct glucocorticoid receptor activity in the limbic system, suppression of CRH feedback, and secondary disruption of serotonin turnover.

Dose reduction is the primary intervention. When dose reduction is not possible, low-dose quetiapine (25 to 50 mg) or valproate has been used off-label to manage steroid-induced mania (7).

Hormonal Contraceptives

Combined oral contraceptive pills (COCPs) and progestin-only preparations affect mood through suppression of endogenous estrogen fluctuations and through the neurosteroid activity of synthetic progestins. A Danish cohort study of 1.06 million women (published in JAMA Psychiatry, 2016) found that hormonal contraceptive users had a 1.8-fold higher rate of first antidepressant prescription compared with non-users, with the highest risk in adolescents (8).

Not every progestin behaves the same. Levonorgestrel and medroxyprogesterone acetate carry greater mood-dampening risk than drospirenone or dienogest in head-to-head observational data.

Beta-Blockers

Propranolol and atenolol cross the blood-brain barrier and reduce central noradrenergic tone. Depression, emotional blunting, and fatigue are reported by 10 to 20% of patients in longer-term use (9). Carvedilol and metoprolol show similar rates in real-world pharmacovigilance data. Switching to a hydrophilic beta-blocker such as nadolol, which has minimal CNS penetration, may resolve mood-related side effects.

Stimulants and ADHD Medications

Amphetamine salts (Adderall) and methylphenidate (Ritalin, Concerta) can produce rebound irritability as plasma levels fall in the afternoon, a phenomenon distinct from any underlying mood disorder. The FDA label for amphetamine salts specifically notes emotional lability as a listed adverse effect (10). Extended-release formulations attenuate this effect by flattening the pharmacokinetic curve.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) have CNS-active receptors, and emerging pharmacovigilance data prompted the FDA to update the semaglutide label in 2023 to include monitoring guidance for suicidal ideation and behavior (11). Most current evidence does not establish causation: a 2024 meta-analysis covering 11 GLP-1 trials found no statistically significant increase in psychiatric adverse events compared with placebo (12). Clinicians should still screen for baseline psychiatric history before initiating these agents.

Isotretinoin

Isotretinoin (Accutane) carries a black-box warning for depression, psychosis, and suicidal ideation. The causal relationship remains debated because severe acne itself causes depression, but the FDA mandates the iPLEDGE risk-management program, which includes monthly mood screening (13).

Opioids and Benzodiazepines

Both drug classes alter mood acutely and during withdrawal. Opioid-induced hypogonadism, in which chronic opioid use suppresses LH and FSH secretion, is an underdiagnosed cause of persistent low mood and irritability in patients on long-term opioid therapy (14).

Drugs That Treat Mood Swings

Choosing the right drug depends entirely on the underlying mechanism. A clinician who conflates perimenopausal mood instability with bipolar II disorder will prescribe the wrong class.

SSRIs and SNRIs

Selective serotonin reuptake inhibitors remain the first-line pharmacologic option for mood dysregulation tied to major depressive disorder, anxiety, and PMDD. The CANMAT 2016 clinical practice guidelines for depression list escitalopram and sertraline as first-choice agents based on efficacy-to-tolerability balance (15).

For PMDD specifically, fluoxetine 20 mg daily or as a luteal-phase-only regimen (taken only in the 14 days before menstruation) is FDA-approved and produces a 50% or greater reduction in symptom severity in roughly 60% of patients (16).

Mood Stabilizers

Lithium carbonate is the reference standard for bipolar spectrum disorders. A Cochrane review (last updated 2019) covering 9 randomized controlled trials confirmed that lithium reduces the rate of any mood episode relapse by approximately 40% compared with placebo (17). Target serum levels of 0.6 to 1.0 mEq/L are required for prophylaxis; levels above 1.5 mEq/L carry toxicity risk.

Valproate (divalproex sodium) and lamotrigine are commonly used alternatives. Lamotrigine shows particular efficacy for bipolar depression rather than mania (18). Valproate is teratogenic and carries a black-box warning; it should not be used in people who might become pregnant without a strong contraceptive plan (19).

Atypical Antipsychotics

Quetiapine (Seroquel), aripiprazole (Abilify), and lurasidone (Latuda) all carry FDA indications for bipolar depression or maintenance. Quetiapine XR at 50 to 300 mg also reduces anxiety-driven emotional lability in patients without a primary bipolar diagnosis, though this is off-label use (20).

Hormone Therapy for Perimenopausal Mood Swings

The North American Menopause Society (NAMS) 2022 position statement states directly: "Hormone therapy is the most effective treatment for vasomotor symptoms and associated mood changes in perimenopausal and early postmenopausal women." Transdermal estradiol (0.05 to 0.1 mg/day patch) avoids first-pass hepatic metabolism and produces steadier serum levels than oral estrogen, reducing the fluctuation-driven mood variability seen with oral formulations (21).

A randomized controlled trial published in JAMA Psychiatry (Gordon et al., 2018, N=172) found that transdermal estradiol plus progesterone reduced new-onset perimenopausal depressive symptoms by 32.3% compared with placebo at 12 months (22).

For women who have undergone hysterectomy, estrogen-only therapy is appropriate. Women with an intact uterus require a progestogen added to protect the endometrium; micronized progesterone (Prometrium) is preferred over synthetic progestins because it has a more neutral mood profile due to its allopregnanolone metabolite, which is GABA-A positive (23).

Testosterone Replacement Therapy

Men with confirmed hypogonadism (total testosterone below 300 ng/dL on two morning measurements, per Endocrine Society 2018 guidelines) show statistically significant improvements in mood and depressive symptoms after testosterone replacement (24). The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, confirmed cardiovascular non-inferiority of testosterone treatment and also reported no increase in psychiatric adverse events in the treatment arm (25).

Standard starting doses are testosterone cypionate 50 to 100 mg weekly by intramuscular or subcutaneous injection, or a 1.62% testosterone gel (1 to 2 pumps daily). Dose titration targets a mid-range serum level of 400 to 700 ng/dL.

Non-Hormonal Options for Specific Populations

Venlafaxine 75 mg daily reduces vasomotor-related mood symptoms in breast cancer survivors who cannot use estrogen, per a 2003 randomized trial in The Lancet (26). Pregabalin and gabapentin show modest benefits for anxiety-driven mood instability but carry sedation and dependence risks that limit long-term use.

How Mood Swings Are Diagnosed

Diagnosis is a two-stage process: rule out organic and drug-induced causes first, then evaluate for primary psychiatric disorders.

Lab Workup

A standard initial panel includes:

• TSH and free T4 (thyroid function)
• Complete metabolic panel (glucose, liver enzymes, electrolytes)
• CBC with differential
• Fasting insulin and HbA1c if metabolic syndrome is suspected
• Total and free testosterone, LH, FSH, SHBG
• Estradiol and progesterone (timed to cycle day in premenopausal women)
• Serum cortisol (if Cushing syndrome is in the differential)
• Vitamin D and B12 (deficiencies of both are associated with depressive symptoms)

Structured Psychiatric Screening

The Mood Disorder Questionnaire (MDQ) is a validated, 13-item self-report tool that screens for bipolar spectrum disorders with a sensitivity of 73% and specificity of 90% in outpatient populations (27). The PHQ-9 screens for major depressive disorder; a score of 10 or above suggests at least moderate depression warranting treatment (28).

The Daily Record of Severity of Problems (DRSP) is the gold-standard diary tool for PMDD, requiring at least two consecutive menstrual cycles of prospective symptom tracking before a diagnosis can be confirmed (29).

Medication Review

Every clinician evaluating mood swings should perform a complete medication reconciliation before attributing symptoms to a primary psychiatric condition. Drug-induced mood changes resolve when the offending agent is stopped or the dose is reduced, and adding a second psychotropic without first addressing the causative drug creates unnecessary polypharmacy.

When Should You Worry About Mood Swings?

Brief mood variation is normal. Concern rises when shifts are disproportionate in intensity, duration, or frequency relative to life circumstances.

Clinical Red Flags

Seek same-week evaluation for any of the following:

• Mood episodes lasting more than 2 weeks without a clear external trigger
• Euphoric episodes with decreased sleep (less than 3 hours) and pressured speech (possible bipolar I mania)
• Irritability accompanied by thoughts of harming self or others
• Mood swings that began or worsened within 4 weeks of starting a new medication
• Significant functional impairment at work, school, or in relationships

The American Psychiatric Association's DSM-5-TR criteria require that mood episodes cause "clinically significant distress or impairment in social, occupational, or other important areas of functioning" to meet diagnostic thresholds (30).

Suicidal Ideation

Any active suicidal ideation warrants emergency evaluation. The FDA mandates a black-box warning on all antidepressants stating that use in patients age <25 is associated with increased risk of suicidal thinking and behavior, particularly in the first 1 to 4 weeks of treatment (31). Patients and caregivers should be counseled on this risk at every antidepressant initiation.

Lifestyle and Non-Drug Interventions That Reduce Mood Swings

Pharmacotherapy works better alongside structured behavioral changes. These are not optional extras; they have quantified effect sizes.

Exercise

Aerobic exercise at 150 minutes per week (as recommended by the CDC's Physical Activity Guidelines) reduces depressive symptoms with an effect size comparable to antidepressants in mild-to-moderate depression, per a 2016 Cochrane review of 35 trials (32). Resistance training shows a similar benefit for mood and is particularly well-supported in older adults.

Cognitive Behavioral Therapy

CBT reduces mood episode frequency in bipolar II disorder. A 2010 randomized trial in Archives of General Psychiatry (N=204) found that adding CBT to pharmacotherapy reduced time ill by 2.2 months over an 18-month follow-up compared with medication alone (33).

Sleep Hygiene

Sleep restriction is both a symptom and a trigger of mood instability. Maintaining a consistent sleep-wake schedule within a 30-minute window seven days a week is one of the most evidence-supported behavioral interventions for mood stabilization in bipolar disorder (34).

Alcohol Reduction

Alcohol is a CNS depressant and disrupts REM sleep architecture. Even moderate consumption of 2 drinks per day is associated with higher rates of depressive episodes in longitudinal cohorts (35). Patients on mood stabilizers should be informed that alcohol substantially increases sedation and impairs medication efficacy.